Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Companion Diagnostics Market
The global companion diagnostics market was valued at USD 8,325.24 million in 2025 and is projected to reach USD 26,322.39 million by 2035, expanding at a compound annual growth rate (CAGR) of 12.2% over the forecast period.
Market size
Growth trajectory through 2035
Companion Diagnostics Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01
- [data not available in current sources]: [data not available in current sources].
-
Development 02
- [data not available in current sources]: [data not available in current sources].
-
Development 03
- [data not available in current sources]: [data not available in current sources].
Emerging opportunities added
- Integration with digital health and AI The convergence of companion diagnostics with digital health platforms and artificial intelligence (AI) presents opportunities to improve data analytics, predictive modeling, and real-time monitoring. These technologies can enhance the precision and utility of diagnostic tools.
- Expansion in emerging markets Rapidly growing healthcare infrastructure and increasing healthcare expenditure in regions such as Asia-Pacific and Latin America offer untapped potential for companion diagnostics. Local partnerships and tailored solutions can help address region-specific needs.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $8.33 Bn
- CAGR
- 12.20%
- Expansion
- 3.2×
Market shape
top segment · 46.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High cost of development and implementation
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
[data not available in current sources]: [data not available in current sources]
+2 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 124-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Companion Diagnostics Market today ($8.33 Bn base), and how fast will it grow at 12.2% CAGR through 2035?
- Which of Assays, Kits & Reagents, Software & Services holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Infectious Disease Diagnosis, Genetic Diagnosis, Oncology applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rise of personalized medicine) and top restraints (led by High cost of development and implementation), with quantified CAGR impact?
- What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rise of personalized medicine The growing emphasis on tailored therapeutic approaches is increasing the need for companion diagnostics to guide treatment decisions. This trend is particularly evident in oncology, where targeted therapies require accurate diagnostic tools to identify eligible patients.
- Technological advancements in diagnostic platforms Innovations in polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization (ISH) are enhancing the accuracy and efficiency of companion diagnostics. These advancements are enabling faster and more reliable detection of biomarkers.
- Increasing prevalence of chronic and infectious diseases The rising burden of conditions such as cancer and infectious diseases is driving demand for companion diagnostics to improve early detection, treatment selection, and patient outcomes. Regulatory support for these tools further accelerates market growth.
Restraints
Holding it back
- High cost of development and implementation The research, development, and regulatory approval processes for companion diagnostics are resource-intensive, limiting market entry for smaller firms and increasing overall costs for healthcare systems.
- Complex regulatory landscape Stringent regulatory requirements for companion diagnostics, particularly in the U.S. and Europe, can delay market approval and increase compliance burdens. This complexity may deter investment and slow innovation.
- Limited reimbursement policies Inconsistent reimbursement frameworks across regions can restrict adoption of companion diagnostics, particularly in price-sensitive markets. This challenge is compounded by the need for healthcare providers to balance diagnostic costs with clinical benefits.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rise of personalized medicine | +5.5% | Global | 2025–2035 |
| Technological advancements in diagnostic platforms | +3.4% | Global | 2025–2035 |
| Increasing prevalence of chronic and infectious diseases | +2.7% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High cost of development and implementation | −2.2% | Global | 2025–2029 |
| Complex regulatory landscape | −1.5% | Global | 2025–2029 |
| Limited reimbursement policies | −1.1% | Global | 2025–2029 |
The companion diagnostics market is segmented by product type, technology, indication, end user, and region. These dimensions reflect the diverse applications and stakeholders involved in the market.
Revenue share by type · 2025 base year
% OF $8.33 BN COMPANION DIAGNOSTICS MARKET · 3 TYPES COVERED
Each slice = that type's share of the total $8.33 Bn Companion Diagnostics Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Assays
-
Kits & Reagents
-
Software & Services
By application
-
Infectious Disease Diagnosis
-
Genetic Diagnosis
-
Oncology
-
Blood Screening
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $8.33 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.7% in 2025. The region is expected to maintain a leading position in the companion diagnostics market, driven by advanced healthcare infrastructure, high adoption of personalized medicine, and significant invest…
Per-region detail
-
North America
The region is expected to maintain a leading position in the companion diagnostics market, driven by advanced healthcare infrastructure, high adoption of personalized medicine, and significant investments in research and development
-
Europe
Europe is a key market for companion diagnostics, supported by strong regulatory frameworks, increasing focus on oncology, and collaborations between diagnostic developers and pharmaceutical companies
-
Asia-Pacific
The Asia-Pacific region is projected to experience rapid growth, fueled by rising healthcare expenditure, growing awareness of companion diagnostics, and expanding healthcare access in countries such as China and India
-
Latin America
Growth in Latin America is driven by improving healthcare systems and partnerships with global diagnostic companies. However, economic constraints and regulatory hurdles may limit the pace of adoption
-
Middle East & Africa
The market in this region is nascent but holds potential due to increasing healthcare investments and partnerships aimed at addressing regional health challenges, particularly in oncology and infectious diseases
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The companion diagnostics market is moderately concentrated, with a mix of large pharmaceutical companies and specialized diagnostic firms competing for market share. Key players leverage partnerships with pharmaceutical companies to align their diagnostic tools with targeted therapies.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of companion diagnostics market?
The companion diagnostics market size had crossed USD 3.5 Billion in 2020 and will observe a CAGR of more than 13.34% up to 2029. -
• What are some of the market's driving forces?
Major factors driving the companion diagnostics market growth include the significant growth of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. -
• Which are the top companies to hold the market share in companion diagnostics market?
Qiagen, Agilent Technologies, Roche, Abbott Laboratories, Inc., BioMerieux, Ventana Medical Systems, Myriad Genetics, Inc., Resonance Health Ltd, Leica Microsystems, Life Technologies, F. Hoffmann-L Roche Ltd., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., Danaher Corporation are the major companion diagnostics market players. -
• Which is the largest regional market for companion diagnostics market?
The region's largest share is in North America. Products manufactured in nations like US and Canada that perform similarly and are inexpensively accessible to the general public have led to the increasing appeal.
The Companion Diagnostics Market is projected to reach $26.34 Bn by 2035, up from $8.33 Bn in 2025 — a 12.20% CAGR equating to roughly 3.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.